A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background ACEi and/or ARB Therapy.

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background ACEi and/or ARB Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2012

At a glance

  • Drugs Pamrevlumab (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top